| Literature DB >> 30302119 |
Raha Orfali1, Nasir Ali Siddiqui1, Perwez Alam1, Tawfeq Abdullah Alhowiriny1, Areej Mohammad Al-Taweel1, Sami Al-Yahya2, Najwa Mohammed Majrashi2, Rashad Mehmood3, Shabana Iqrar Khan4, Shagufta Perveen1.
Abstract
Nepeta deflersiana (Lamiaceae) is a well-known medicinal plant that grows in Saudi Arabia. This plant is used in Saudi and Yemeni folk medicine as an anti-inflammatory, carminative, and antirheumatic agent. In order to prove its use in folk medicine, four different extracts from the aerial parts of the plant: petroleum ether, chloroform, ethyl acetate, and n-butanol extracts were subjected to biological assays to screen PPARα and PPAR ϒ agnostic, antioxidant, anti-inflammatory, and cytotoxic activities. Ethyl acetate and n-butanol extracts of N. deflersiana NDEE and NDBE, respectively, showed a decrease in oxidative stress and inhibition of both NF-kB and iNOS activities with no cytotoxic effects on four human cancer cell lines. Both active extracts were standardized using two bioactive metabolites which were isolated from the aerial parts of the same plant [8-epi-7-deoxyloganic acid (compound 1) and Ursolic acid (compound 2)] by developing a validated HPTLC method. It was found to provide a sharp and compact band of compound 1 at Rf = 0.07 and Rf = 0.57 for compound 2, using chloroform, methanol, and formic acid (8.9:0.8:0.3, v/v/v) as mobile phase at 550 nm. Compounds 1 and 2 were found in NDEE by 9.59 %, w/w, and 84.63 %, w/w, respectively, and by 11.97 %, w/w, and 21.26 %, w/w, respectively, in NDBE.Entities:
Year: 2018 PMID: 30302119 PMCID: PMC6158929 DOI: 10.1155/2018/8790769
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Chemical structure of biomarkers 8-epi-7-deoxyloganic acid 1 and Ursolic acid 2.
Figure 21H-NMR spectrum of 1 (CD3OD, 500 MHz).
Figure 313C-NMR spectrum of 1 (CD3OD, 125 MHz).
Figure 41H-NMR spectrum of 2 (DMSO-d6, 700 MHz).
Figure 513C-NMR spectrum of 2 (DMSO-d6, 175 MHz).
PPAR agonistic activity of N. deflersiana extracts.
| Sample name | Fold induction | |||||
|---|---|---|---|---|---|---|
| PPAR alpha | PPAR gamma | |||||
| 50 | 25 | 12.5 | 50 | 25 | 12.5 | |
| Pet. ether extract | NA | NA | NA | NA | NA | NA |
| CHCl3 extract | NA | NA | NA | NA | NA | NA |
| EtOAc extract | 1.48 | 1.06 | 0.87 | 1.6 | 1.2 | 1.0 |
|
| 1.86 | 2.03 | 1.74 | 1.9 | 1.7 | 1.2 |
| Ciprofibrate 10 | 1.9 | - | - | 2.1 | - | - |
| Rosiglitazone 10 | 2.2 | - | - | 2.6 | - | - |
NA= not active.
Anti-inflammatory activity of N. deflersiana extracts.
| aSample Name | % decrease in oxidative stress | Inhibition of NF-kB activity IC50 in | Inhibition of iNOS activity IC50 in |
|---|---|---|---|
| Pet. ether extract | NA | NA | NA |
| CHCl3 extract | NA | NA | NA |
| EtOAc extract | 55 | 17 | 29 |
|
| 52 | 39 | 18 |
| Parthenolideb | - | 0.7 | 0.2 |
| Quercetinb | 74 | - | - |
aAt 1000 µg/ml.
bPositive control, NA: no activity up to 100 μg/mL (NF-kB, iNOS) and 500 μg/mL (oxidative stress).
Cytotoxicity of N. deflersiana extracts.
| Sample Name | Inhibition of cancer cells activity IC50 in | Inhibition of Non-cancer cells activity IC50 in | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Pet. ether extract | NA | NA | NA | NA | NA | NA |
| CHCl3 extract | NA | NA | NA | NA | NA | 55 |
| EtOAc extract | NA | NA | NA | NA | NA | 16 |
|
| NA | NA | NA | NA | NA | NA |
| Doxorubicin | 1.23 | 1.85 | 1.93 | 0.83 | >5 | 0.85 |
NA= no cytotoxic activity up to 100 µg/ml.
Figure 6Quantification of 8-epi-7-deoxyloganic acid 1 and Ursolic acid 2 in different fractions of N. deflersiana by HPTLC using chloroform, methanol, and formic acid (8.9:0.8:0.3, v/v/v) as mobile phase. (a) Chromatogram of standard 1 (Rf = 0.07; 800 ng/spot) and 2 (Rf = 0.57; 800 ng/spot) at λmax= 515 nm. (b) Pictogram of p-anisaldehyde derivatized TLC plate at day light. (c) N. deflersiana n-butanol extract [NDBE (1, spot 2, Rf = 0.07; 2, spot 8, Rf = 0.57)]; (b) N. deflersiana ethyl acetate extract [NDEE (1, spot 2, Rf = 0.07; 2, spot 8, Rf = 0.57)].
Rf, linear regression data for the calibration curve of 8-epi-7-deoxyloganic acid and Ursolic acid (n=6).
|
| 8-epi-7-deoxyloganic acid | Ursolic acid |
|---|---|---|
| Linearity range (ng/spot) | 100-1000 | 100-1000 |
| Regression equation | Y= 4.128X+ 806.99 | Y= 11.91X + 237.26 |
| Correlation | 0.9971 | 0.9955 |
| Slope ± SD | 4.128 ± 0.013 | 11.91 ± 0.045 |
| Intercept ± SD | 806.99 ± 38.77 | 237.26 ± 20.58 |
| Standard error of slope | 0.005 | 0.018 |
| Standard error of intercept | 15.82 | 8.40 |
| Rf | 0.07 ± 0.0001 | 0.57 ± 0.04 |
| LOD | 10.51 | 12.49 |
| LOQ | 31.85 | 37.86 |
Precision of the proposed HPTLC method (n=6).
| Conc. of standard added (ng/spot) | 8-Epi-7-deoxyloganic acid | Ursolic acid | ||||||
|---|---|---|---|---|---|---|---|---|
| Intraday Precision | Interday Precision | Intraday Precision | Interday Precision | |||||
| Average Conc. found ± SD | %RSD | Average Conc. found ± SD | %RSD | Average Conc. found ± SD | %RSD | Average Conc. found ± SD | %RSD | |
| 200 | 198.18±2.47 | 1.24 | 193.33±2.29 | 1.18 | 198.84±2.19 | 1.10 | 197.16±2.09 | 1.06 |
| 400 | 396.67±5.19 | 1.30 | 391.82±5.01 | 1.27 | 396.91±4.61 | 1.16 | 395.23±4.49 | 1.13 |
| 600 | 595.55±8.69 | 1.45 | 590.70±8.33 | 1.41 | 597.76±7.17 | 1.19 | 595.24±7.01 | 1.17 |
Recovery as accuracy studies of the proposed HPTLC Method (n=6).
| (%) of 1 and 2 added to analyte | Theoretical conc. of 1 and 2 ( | Concentration found ( | %RSD | % Recovery | |||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| 0 | 200 | 198.88 ± 2.35 | 196.32 ± 2.49 | 1.181 | 1.26 | 99.44 | 98.16 |
| 50 | 300 | 296.30 ± 3.77 | 295.22 ± 3.81 | 1.27 | 1.29 | 98.76 | 98.40 |
| 100 | 400 | 394.43 ± 5.61 | 396.24 ± 5.37 | 1.42 | 1.35 | 98.60 | 99.06 |
| 150 | 500 | 497.41 ± 7.39 | 494.06 ± 7.33 | 1.48 | 1.48 | 99.48 | 98.81 |
Robustness of the proposed HPTLC Method (n=6).
| Optimization condition |
|
| ||
|---|---|---|---|---|
| SD | %RSD | SD | %RSD | |
|
| ||||
| (8.9:0.8:0.3) | 3.49 | 1.17 | 4.19 | 1.71 |
| (9:0.7:0.3) | 3.51 | 1.18 | 4.17 | 1.70 |
| (8.8:0.9:0.3) | 3.46 | 1.16 | 4.21 | 1.72 |
|
| ||||
| (18 mL) | 3.55 | 1.19 | 4.23 | 1.72 |
| (20 mL) | 3.51 | 1.18 | 4.20 | 1.71 |
| (22 mL) | 3.49 | 1.17 | 4.25 | 1.73 |
|
| ||||
| (10 min) | 3.54 | 1.18 | 4.07 | 1.66 |
| (20 min) | 3.59 | 1.20 | 4.03 | 1.64 |
| (30 min) | 3.51 | 1.18 | 4.09 | 1.67 |